Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: The whitehall II study

Christian Herder, Eric J. Brunner, Wolfgang Rathmann, Klaus Strassburger, Adam G. Tabák, Nanette C. Schloot, Daniel R. Witte

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

OBJECTIVE - Interleukin-1 receptor antagonist (IL-IRa), a natural inhibitor of interleukin-lβ, has been shown to improve β-cell function and glycemic control in patients with type 2 diabetes. The aim of this study was to investigate whether baseline systemic levels of IL-IRa are associated with incident type 2 diabetes during more than 10 years of follow-up. RESEARCH DESIGN AND METHODS - We measured serum IL-IRa concentrations in a nested case-control study (181 case and 376 age-, sex-, and BMI-matched normoglycemic control subjects) within the Whitehall II cohort (U.K.). RESULTS - IL-IRa concentrations were higher in case subjects (P = 0.0006) and associated with incident type 2 diabetes (odds ratio fora 1-SD increase of IL-IRa 1.48 [95% CI 1.21-1.80]). This association remained significant after adjustment for multiple potential confounders but was attenuated by adjusting for 2-h glucose. CONCLUSIONS - Our findings indicate that individuals who will develop type 2 diabetes are characterized by a complex immune activation that also includes upregulation of the anti-inflammatory cytokine IL-IRa.

Original languageEnglish
Pages (from-to)421-423
Number of pages3
JournalDiabetes care
Volume32
Issue number3
DOIs
Publication statusPublished - Mar 1 2009

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Fingerprint Dive into the research topics of 'Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: The whitehall II study'. Together they form a unique fingerprint.

  • Cite this